Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Smoking and Parkinson disease: Evidence for gene-by-smoking interactions.

Lee PC, Ahmed I, Loriot MA, Mulot C, Paul KC, Bronstein JM, Ritz B, Elbaz A.

Neurology. 2018 Feb 13;90(7):e583-e592. doi: 10.1212/WNL.0000000000004953. Epub 2018 Jan 19.

PMID:
29352099
2.

About molecular profile of lung cancer in Tunisian patients.

Mezni F, Mlika M, Boussen H, Ghedira H, Fenniche S, Faten T, Loriot MA.

J Immunoassay Immunochem. 2018;39(1):99-107. doi: 10.1080/15321819.2017.1407339.

PMID:
29308976
3.

Pooled analysis of the HLA-DRB1 by smoking interaction in Parkinson disease.

Chuang YH, Lee PC, Vlaar T, Mulot C, Loriot MA, Hansen J, Lill CM, Ritz B, Elbaz A.

Ann Neurol. 2017 Nov;82(5):655-664. doi: 10.1002/ana.25065. Epub 2017 Oct 26.

PMID:
28981958
4.

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing.

Etienne-Grimaldi MC, Le Guellec CB, Boyer JC, Chatelut E, Evrard A, Loriot MA, Paci A, Royer B, Thomas F, Ciccolini J.

Semin Oncol. 2017 Apr;44(2):159-160. doi: 10.1053/j.seminoncol.2017.06.001. Epub 2017 Jul 4. No abstract available.

PMID:
28923215
5.

A comprehensive characterization of the impact of mycophenolic acid on the metabolism of Jurkat T cells.

Fernández-Ramos AA, Marchetti-Laurent C, Poindessous V, Antonio S, Petitgas C, Ceballos-Picot I, Laurent-Puig P, Bortoli S, Loriot MA, Pallet N.

Sci Rep. 2017 Sep 5;7(1):10550. doi: 10.1038/s41598-017-10338-6.

6.

6-mercaptopurine promotes energetic failure in proliferating T cells.

Fernández-Ramos AA, Marchetti-Laurent C, Poindessous V, Antonio S, Laurent-Puig P, Bortoli S, Loriot MA, Pallet N.

Oncotarget. 2017 Jun 27;8(26):43048-43060. doi: 10.18632/oncotarget.17889.

7.

Pharmacogenetics of immunosuppressants: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics (RNPGx).

Woillard JB, Chouchana L, Picard N, Loriot MA; French Network of Pharmacogenetics (RNPGX).

Therapie. 2017 Apr;72(2):285-299. doi: 10.1016/j.therap.2016.09.016. Epub 2017 Jan 30. Review.

PMID:
28318610
8.

Pharmacogénétique des immunosuppresseurs : état des connaissances et des pratiques – recommandations du Réseau national de pharmacogénétique (RNPGx).

Woillard JB, Chouchana L, Picard N, Loriot MA; Réseau national de pharmacogénétique (RNPGx).

Therapie. 2017 Apr;72(2):269-284. doi: 10.1016/j.therap.2016.09.011. Epub 2017 Jan 3. French. No abstract available.

PMID:
28242127
9.

Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx).

Picard N, Boyer JC, Etienne-Grimaldi MC, Barin-Le Guellec C, Thomas F, Loriot MA; French National Network of Pharmacogenetics (RNPGx).

Therapie. 2017 Apr;72(2):185-192. doi: 10.1016/j.therap.2016.09.014. Epub 2017 Jan 30. Review.

PMID:
28237406
10.

Traitements personnalisés grâce à la pharmacogénétique : niveaux de preuve et de recommandations du Réseau national de pharmacogénétique (RNPGx).

Picard N, Boyer JC, Etienne-Grimaldi MC, Barin-Le Guellec C, Thomas F, Loriot MA; Réseau national de pharmacogénétique (RNPGx).

Therapie. 2017 Apr;72(2):175-183. doi: 10.1016/j.therap.2016.09.007. Epub 2017 Jan 3. French. No abstract available.

PMID:
28153355
11.

Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.

Gallien S, Journot V, Loriot MA, Sauvageon H, Morlat P, Reynes J, Reliquet V, Chêne G, Molina JM; ANRS 099 ALIZE trial study group.

HIV Med. 2017 Sep;18(8):537-545. doi: 10.1111/hiv.12488. Epub 2017 Feb 1.

PMID:
28145050
12.

Pegylated liposomal doxorubicin (Caelyx®) interference with the spectrophotometric Jaffe method for quantitative determination of creatinine in human plasma.

Blel A, Orven Y, Pallet N, Chasse JF, Vedie B, Loriot MA, Paul JL, Narjoz C.

Clin Biochem. 2017 May;50(7-8):455-457. doi: 10.1016/j.clinbiochem.2016.12.002. Epub 2016 Dec 14. No abstract available.

PMID:
27988325
13.

Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes.

Flahault A, Anglicheau D, Loriot MA, Thervet E, Pallet N.

Pharmacogenomics. 2017 Jan;18(2):165-173. doi: 10.2217/pgs-2016-0146. Epub 2016 Dec 15.

PMID:
27977332
14.

Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin.

Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem JE, Narjoz C, Gaussem P, Beaune P, Funck-Brentano C, Azizi M, Mismetti P, Loriot MA.

J Thromb Haemost. 2017 Feb;15(2):273-283. doi: 10.1111/jth.13577. Epub 2017 Feb 6.

PMID:
27893182
15.

Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.

Isvoran A, Louet M, Vladoiu DL, Craciun D, Loriot MA, Villoutreix BO, Miteva MA.

Drug Discov Today. 2017 Feb;22(2):366-376. doi: 10.1016/j.drudis.2016.09.015. Epub 2016 Sep 28. Review.

PMID:
27693711
16.

Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening.

Damon C, Luck M, Toullec L, Etienne I, Buchler M, Hurault de Ligny B, Choukroun G, Thierry A, Vigneau C, Moulin B, Heng AE, Subra JF, Legendre C, Monnot A, Yartseva A, Bateson M, Laurent-Puig P, Anglicheau D, Beaune P, Loriot MA, Thervet E, Pallet N.

Am J Transplant. 2017 Apr;17(4):1008-1019. doi: 10.1111/ajt.14040. Epub 2016 Oct 7.

PMID:
27597269
17.

The effect of immunosuppressive molecules on T-cell metabolic reprogramming.

Fernández-Ramos AA, Poindessous V, Marchetti-Laurent C, Pallet N, Loriot MA.

Biochimie. 2016 Aug;127:23-36. doi: 10.1016/j.biochi.2016.04.016. Epub 2016 Apr 25. Review.

PMID:
27126071
18.

Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype.

Pallet N, Etienne I, Buchler M, Bailly E, Hurault de Ligny B, Choukroun G, Colosio C, Thierry A, Vigneau C, Moulin B, Le Meur Y, Heng AE, Legendre C, Beaune P, Loriot MA, Thervet E.

Am J Transplant. 2016 Sep;16(9):2670-5. doi: 10.1111/ajt.13788. Epub 2016 Apr 8.

19.

A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients.

Jannot AS, Vuillemin X, Etienne I, Buchler M, Hurault de Ligny B, Choukroun G, Colosio C, Thierry A, Vigneau C, Moulin B, Rerolle JP, Heng AE, Subra JF, Legendre C, Beaune P, Loriot MA, Thervet E, Pallet N.

Ther Drug Monit. 2016 Apr;38(2):223-9. doi: 10.1097/FTD.0000000000000267.

PMID:
26829596
20.

High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study.

Manfredi S, Bouché O, Rougier P, Dahan L, Loriot MA, Aparicio T, Etienne PL, Lafargue JP, Lécaille C, Legoux JL, Le Malicot K, Maillard E, Lecomte T, Khemissa F, Breysacher G, Michel P, Mitry E, Bedenne L.

Mol Cancer Ther. 2015 Dec;14(12):2782-8. doi: 10.1158/1535-7163.MCT-15-0293. Epub 2015 Oct 22.

21.

Gene expression profiling of cytochromes P450, ABC transporters and their principal transcription factors in the amygdala and prefrontal cortex of alcoholics, smokers and drug-free controls by qRT-PCR.

Toselli F, de Waziers I, Dutheil M, Vincent M, Wilce PA, Dodd PR, Beaune P, Loriot MA, Gillam EM.

Xenobiotica. 2015;45(12):1129-37. doi: 10.3109/00498254.2015.1040102. Epub 2015 Jun 22.

PMID:
26095139
22.

Molecular insight into thiopurine resistance: transcriptomic signature in lymphoblastoid cell lines.

Chouchana L, Fernández-Ramos AA, Dumont F, Marchetti C, Ceballos-Picot I, Beaune P, Gurwitz D, Loriot MA.

Genome Med. 2015 Apr 18;7(1):37. doi: 10.1186/s13073-015-0150-6. eCollection 2015.

23.

Expression in yeast, new substrates, and construction of a first 3D model of human orphan cytochrome P450 2U1: Interpretation of substrate hydroxylation regioselectivity from docking studies.

Ducassou L, Jonasson G, Dhers L, Pietrancosta N, Ramassamy B, Xu-Li Y, Loriot MA, Beaune P, Bertho G, Lombard M, Mansuy D, André F, Boucher JL.

Biochim Biophys Acta. 2015 Jul;1850(7):1426-37. doi: 10.1016/j.bbagen.2015.03.014. Epub 2015 Apr 7.

PMID:
25857771
24.

UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.

Etienne-Grimaldi MC, Boyer JC, Thomas F, Quaranta S, Picard N, Loriot MA, Narjoz C, Poncet D, Gagnieu MC, Ged C, Broly F, Le Morvan V, Bouquié R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C; Collective work by Groupe de Pharmacologie Clinique Oncologique (GPCO-Unicancer); French Réseau National de Pharmacogénétique Hospitalière (RNPGx).

Fundam Clin Pharmacol. 2015 Jun;29(3):219-37. doi: 10.1111/fcp.12117. Epub 2015 May 4.

PMID:
25817555
25.

A case of respiratory depression in a child with ultrarapid CYP2D6 metabolism after tramadol.

Orliaguet G, Hamza J, Couloigner V, Denoyelle F, Loriot MA, Broly F, Garabedian EN.

Pediatrics. 2015 Mar;135(3):e753-5. doi: 10.1542/peds.2014-2673. Epub 2015 Feb 2.

26.

Rituximab or azathioprine maintenance in ANCA-associated vasculitis.

Chouchana L, Beaune P, Loriot MA.

N Engl J Med. 2015 Jan 22;372(4):386. doi: 10.1056/NEJMc1414728#SA3. No abstract available.

PMID:
25607436
27.

Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations.

Pallet N, Jannot AS, El Bahri M, Etienne I, Buchler M, de Ligny BH, Choukroun G, Colosio C, Thierry A, Vigneau C, Moulin B, Le Meur Y, Heng AE, Subra JF, Legendre C, Beaune P, Alberti C, Loriot MA, Thervet E.

Am J Transplant. 2015 Mar;15(3):800-5. doi: 10.1111/ajt.13059. Epub 2015 Jan 14.

28.

An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population.

Krishna Kumar D, Shewade DG, Loriot MA, Beaune P, Sai Chandran BV, Balachander J, Adithan C.

Eur J Clin Pharmacol. 2015 Feb;71(2):173-81. doi: 10.1007/s00228-014-1791-x. Epub 2014 Dec 19.

PMID:
25519826
29.

Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers.

Lenuzza N, Duval X, Nicolas G, Thévenot E, Job S, Videau O, Narjoz C, Loriot MA, Beaune P, Becquemont L, Mentré F, Funck-Brentano C, Alavoine L, Arnaud P, Delaforge M, Bénech H.

Eur J Drug Metab Pharmacokinet. 2016 Apr;41(2):125-38. doi: 10.1007/s13318-014-0239-0. Epub 2014 Dec 3.

PMID:
25465228
30.

Lack of replication of the GRIN2A-by-coffee interaction in Parkinson disease.

Ahmed I, Lee PC, Lill CM, Searles Nielsen S, Artaud F, Gallagher LG, Loriot MA, Mulot C, Nacfer M, Liu T, Biernacka JM, Armasu S, Anderson K, Farin FM, Lassen CF, Hansen J, Olsen JH, Bertram L, Maraganore DM, Checkoway H, Ritz B, Elbaz A.

PLoS Genet. 2014 Nov 20;10(11):e1004788. doi: 10.1371/journal.pgen.1004788. eCollection 2014 Nov. No abstract available.

31.

Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.

Narjoz C, Cessot A, Thomas-Schoemann A, Golmard JL, Huillard O, Boudou-Rouquette P, Behouche A, Taieb F, Durand JP, Dauphin A, Coriat R, Vidal M, Tod M, Alexandre J, Loriot MA, Goldwasser F, Blanchet B.

Invest New Drugs. 2015 Feb;33(1):257-68. doi: 10.1007/s10637-014-0178-2. Epub 2014 Oct 25.

PMID:
25344452
32.

Impact of aspirin and clopidogrel interruption on platelet function in patients undergoing major vascular surgery.

Le Manach Y, Kahn D, Bachelot-Loza C, Le Sache F, Smadja DM, Remones V, Loriot MA, Coriat P, Gaussem P.

PLoS One. 2014 Aug 20;9(8):e104491. doi: 10.1371/journal.pone.0104491. eCollection 2014.

33.

[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].

Boyer JC, Etienne-Grimaldi MC, Thomas F, Quaranta S, Picard N, Loriot MA, Poncet D, Gagnieu MC, Ged C, Broly F, Le Morvan V, Bouquié R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C.

Bull Cancer. 2014 Jun;101(6):533-53. doi: 10.1684/bdc.2014.1933. Review. French.

PMID:
24977443
34.

Interindividual variability in TPMT enzyme activity: 10 years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring.

Chouchana L, Narjoz C, Roche D, Golmard JL, Pineau B, Chatellier G, Beaune P, Loriot MA.

Pharmacogenomics. 2014 Apr;15(6):745-57. doi: 10.2217/pgs.14.32.

35.

Association between high antitumor activity of oxaliplatin and cyclophosphamide and constitutional GSTM1 homozygous deletion in an advanced ovarian cancer patient.

Gataa I, Emile G, Loriot MA, Goldwasser F, Alexandre J.

Chemotherapy. 2013;59(4):290-3. doi: 10.1159/000357517. Epub 2014 Jan 24.

PMID:
24480791
36.

Phenome-wide association studies on a quantitative trait: application to TPMT enzyme activity and thiopurine therapy in pharmacogenomics.

Neuraz A, Chouchana L, Malamut G, Le Beller C, Roche D, Beaune P, Degoulet P, Burgun A, Loriot MA, Avillach P.

PLoS Comput Biol. 2013;9(12):e1003405. doi: 10.1371/journal.pcbi.1003405. Epub 2013 Dec 26.

37.

A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone.

Moreau C, Pautas E, Duverlie C, Berndt C, Andro M, Mahé I, Emmerich J, Lacut K, Le Gal G, Peyron I, Gouin-Thibault I, Golmard JL, Loriot MA, Siguret V.

Thromb Haemost. 2014 Apr 1;111(4):705-12. doi: 10.1160/TH13-07-0555. Epub 2013 Dec 12.

PMID:
24337438
38.

Pooled analysis of iron-related genes in Parkinson's disease: association with transferrin.

Rhodes SL, Buchanan DD, Ahmed I, Taylor KD, Loriot MA, Sinsheimer JS, Bronstein JM, Elbaz A, Mellick GD, Rotter JI, Ritz B.

Neurobiol Dis. 2014 Feb;62:172-8. doi: 10.1016/j.nbd.2013.09.019. Epub 2013 Oct 8.

39.

A case of 5-FU-related severe toxicity associated with the p.Y186C DPYD variant.

Zaanan A, Dumont LM, Loriot MA, Taieb J, Narjoz C.

Clin Pharmacol Ther. 2014 Feb;95(2):136. doi: 10.1038/clpt.2013.183. Epub 2013 Sep 13. No abstract available.

PMID:
24037119
40.

Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.

Krishna Kumar D, Shewade DG, Loriot MA, Beaune P, Balachander J, Sai Chandran BV, Adithan C.

Eur J Clin Pharmacol. 2014 Jan;70(1):47-56. doi: 10.1007/s00228-013-1581-x. Epub 2013 Sep 10.

PMID:
24019055
41.

Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants.

Heckman MG, Elbaz A, Soto-Ortolaza AI, Serie DJ, Aasly JO, Annesi G, Auburger G, Bacon JA, Boczarska-Jedynak M, Bozi M, Brighina L, Chartier-Harlin MC, Dardiotis E, Destée A, Ferrarese C, Ferraris A, Fiske B, Gispert S, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyratzi E, Lin CH, Lohmann K, Loriot MA, Lynch T, Mellick GD, Mutez E, Opala G, Park SS, Petrucci S, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Tomiyama H, Uitti RJ, Valente EM, Vassilatis DK, Vilariño-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Xiromerisiou G, Maraganore DM, Farrer MJ, Ross OA; Genetic Epidemiology Of Parkinson's Disease (GEO-PD) Consortium.

Neurobiol Aging. 2014 Jan;35(1):266.e5-14. doi: 10.1016/j.neurobiolaging.2013.07.013. Epub 2013 Aug 17.

42.

Poor response to thiopurine in inflammatory bowel disease: how to overcome therapeutic resistance?

Chouchana L, Roche D, Jian R, Beaune P, Loriot MA.

Clin Chem. 2013 Jul;59(7):1023-6. doi: 10.1373/clinchem.2012.195750. No abstract available.

43.

Genetic resistance to warfarin therapy masked by amiodarone in a 2-year-old girl with mitral valve replacement.

Moreau C, Bajolle F, Siguret V, Loriot MA, Bonnet D.

J Thromb Haemost. 2013 Mar;11(3):555-72. doi: 10.1111/jth.12105. No abstract available.

44.

Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.

Smires FZ, Habbal R, Moreau C, Assaidi A, Loriot MA, Nadifi S.

Pathol Biol (Paris). 2013 Jun;61(3):88-92. doi: 10.1016/j.patbio.2012.10.002. Epub 2012 Nov 30.

PMID:
23201087
45.

Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.

Danese E, Montagnana M, Johnson JA, Rettie AE, Zambon CF, Lubitz SA, Suarez-Kurtz G, Cavallari LH, Zhao L, Huang M, Nakamura Y, Mushiroda T, Kringen MK, Borgiani P, Ciccacci C, Au NT, Langaee T, Siguret V, Loriot MA, Sagreiya H, Altman RB, Shahin MH, Scott SA, Khalifa SI, Chowbay B, Suriapranata IM, Teichert M, Stricker BH, Taljaard M, Botton MR, Zhang JE, Pirmohamed M, Zhang X, Carlquist JF, Horne BD, Lee MT, Pengo V, Guidi GC, Minuz P, Fava C.

Clin Pharmacol Ther. 2012 Dec;92(6):746-56. doi: 10.1038/clpt.2012.184. Epub 2012 Nov 7. Review.

46.

[Vitamin K antagonists: from discovery to pharmacogenetics].

Moreau C, Loriot MA, Siguret V.

Ann Biol Clin (Paris). 2012 Oct 1;70(5):539-51. doi: 10.1684/abc.2012.0740. Review. French.

PMID:
23047901
47.

Collapsing glomerulopathy associated lupus in a black female with homozygous APOL1 mutation.

Kofman T, Narjoz C, Raimbourg Q, Loriot MA, Karras A, Roland M, Hill G, Jacquot C, Nochy D, Thervet E.

Lupus. 2012 Nov;21(13):1459-62. doi: 10.1177/0961203312460114. Epub 2012 Sep 5.

PMID:
22952321
48.

Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.

Boudou-Rouquette P, Narjoz C, Golmard JL, Thomas-Schoemann A, Mir O, Taieb F, Durand JP, Coriat R, Dauphin A, Vidal M, Tod M, Loriot MA, Goldwasser F, Blanchet B.

PLoS One. 2012;7(8):e42875. doi: 10.1371/journal.pone.0042875. Epub 2012 Aug 13.

49.

Hepatic necrosis and hemorrhage following hyperthermic intraperitoneal chemotherapy with oxaliplatin: A review of two cases.

Bouchereau M, Gervais MK, Sideris L, Loriot MH, Ahern SP, Dubé P.

J Gastrointest Oncol. 2011 Jun;2(2):113-6. doi: 10.3978/j.issn.2078-6891.2011.012. No abstract available.

50.

Association between Parkinson's disease and the HLA-DRB1 locus.

Ahmed I, Tamouza R, Delord M, Krishnamoorthy R, Tzourio C, Mulot C, Nacfer M, Lambert JC, Beaune P, Laurent-Puig P, Loriot MA, Charron D, Elbaz A.

Mov Disord. 2012 Aug;27(9):1104-10. doi: 10.1002/mds.25035. Epub 2012 Jul 13.

PMID:
22807207

Supplemental Content

Loading ...
Support Center